ACLARIS THERAPEUTICS INC
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 101
- Market Cap
- $84.9M
- Website
- http://www.aclaristx.com
Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis
Phase 2
Completed
- Conditions
- Seborrheic Keratosis
- Interventions
- Drug: A-101 VehicleDrug: A-101 (40) Topical SolutionDrug: A-101 (32.5) Topical Solution
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT02160626
- Locations
- 🇺🇸
The Education & Research Foundation, Inc., Lynchburg, Virginia, United States
🇺🇸Oregon Medical Research Center, Portland, Oregon, United States
🇺🇸Gwinnett Clinical Research Center, Inc., Snellville, Georgia, United States
Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis
Phase 1
Completed
- Conditions
- Seborrheic Keratosis (SK)
- Interventions
- Drug: A-101 25%Drug: A-101 32.5%Drug: A-101 40%Drug: A-101 Vehicle
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT01986920
- Locations
- 🇺🇸
DermResearch, Inc., Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath